Progesterone decreases the relaxing effect of the beta3-adrenergic receptor agonist BRL 37344 in the pregnant rat myometrium.
Although the published results regarding the function of the beta(3)-adrenergic receptors (beta(3)-ARs) in the regulation of smooth muscle activity are very promising, the question of the mechanism of beta(3)-ARs' action in the pregnant myometrium cannot be fully answered by human investigations. To assess whether it possesses an essential role in the regulation of uterine contractility in pregnant rats, as in humans, we performed functional, western blotting and molecular biology experiments on the late-pregnant rat myometrium. The influence of progesterone on the function of the beta(3)-ARs was also investigated. We demonstrated the presence and the functional activity of the beta(3)-ARs in the late-pregnant rat myometrium. The maximum dose-dependent uterus-relaxing effect of the selective beta(3)-agonist BRL 37344 was recorded at the end of pregnancy in rats, similarly as in humans. The extent of its relaxing action was regarded as moderate. The expression of beta(3)-AR protein and mRNA remained unchanged during the investigated period. The administration of progesterone had no effect on the beta(3)-AR mRNA and protein expression or the maximum relaxation effect of BRL 37344, but shifted the dose-response curve to the right and decreased the synthesis of the second messenger, cAMP. It can be concluded that the beta(3)-ARs play an additional role in the regulation of the contractile activity of the pregnant rat uterus. The inhibitory effect of progesterone on the functional activity of the beta(3)-ARs may have important consequences in the case of human application if this effect is also demonstrated in pregnant human myometrial tissue.
Minorics
Renáta
R
Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary.
Gáspár
Róbert
R
Gál
Adrienn
A
Klukovits
Anna
A
Falkay
George
G
D000322:Adrenergic Agonists / Q000494:pharmacology*; D058667:Adrenergic beta-3 Receptor Agonists; D000818:Animals; D015153:Blotting, Western / Q000379:methods; D000242:Cyclic AMP / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004983:Ethanolamines / Q000494:pharmacology*; D005260:Female; D009126:Muscle Relaxation / Q000187:drug effects; D009215:Myometrium / Q000187:drug effects* / Q000502:physiology; D011247:Pregnancy; D011374:Progesterone / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D014590:Uterine Contraction / Q000187:drug effects*
D000322:Adrenergic Agonists; D058667:Adrenergic beta-3 Receptor Agonists; D004983:Ethanolamines; D012333:RNA, Messenger; D011374:Progesterone; C057368:BRL 37344; D000242:Cyclic AMP